Tools   Select Another Resource Report Type

http://www.bcw.edu/bcw/OrganTissueDonation/WisconsinTissueBank/index.htm

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on January 2,2026. A non-profit program providing tissue procurement services to the state of Wisconsin. The Wisconsin Tissue Bank handles organ donation, works with organ donors, provides organ donation information and organ transplantation. The Wisconsin Tissue Bank staff provides service to hospitals, Medical Examiners/Coroners and Funeral Directors throughout the state of Wisconsin for the recovery of bone, related soft tissue, veins, skin, and cardiovascular tissue for donation and transplantation. The Wisconsin Tissue Bank is dedicated to the education of health care professionals and the public to promote organ and tissue donation. The Wisconsin Tissue Bank promotes an environment sensitive to the physical, emotional, spiritual, social and economic needs of both those served and those who provide the service.

Proper citation: Wisconsin Tissue Bank (RRID:SCR_004910) Copy   

•   Source: SciCrunch Registry

http://www.lcnw.org/medical/tissue-services/

Northwest Tissue Services is the only fully accredited non-profit tissue bank in this region. As a non-profit tissue bank, we provide all allograft and tissue products at the lowest possible cost consistent with high quality. Our accreditation by the American Association of Tissue Banks (AATB) is a testament to the quality and safety of tissue we have provided to hospitals and patients in this region for over twenty years. As the most knowledgeable and experienced tissue resource in the Northwest, we work hard every day to provide high quality tissue products and services.

Proper citation: Northwest Tissue Services (RRID:SCR_004875) Copy   

•   Source: SciCrunch Registry

https://htrn.osu.edu/Pages/Default.aspx

Collect, bank, and distribute human tissue and fluid specimens by uniting tissue-based research resources within the OSU Department of Pathology and promoting collaborative research within the OSU Medical Center and related national human research projects. The HTRN is comprised of the Pathology Core Facility (PCF), Tissue Archive Service (TAS), Tissue Procurement Service (TPS), AIDS and Cancer Specimen Resource (ACSR), the Cancer and Leukemia Group B Pathology Coordinating Office (CALGB - PCO), and an Adenoma Polyp Tissue Bank (APTB).

Proper citation: Human Tissue Resource Network (RRID:SCR_004785) Copy   

•   Source: SciCrunch Registry

http://www.wanprc.org/primate-resources/pathology-tissue-program/

A comparative pathology unit offering pathology support, training programs, and a Tissue Distribution Program (TDP). The TDP provides a wide variety of nonhuman primate tissues to investigative groups within and outside the Washington National Primate Research Center (WaNPRC). Tissue and pathology services (ACVP board certified Veterinary Pathologists), full histology services (including immunohistochemistry and frozen sectioning), and protocol development consultation are available. The Pathology and Tissue Program is an integration of comparative pathology activities occurring at the Washington National Primate Research Center and those occurring within the University of Washington Department of Comparative Medicine ((DCM). Using this model, Washington National Primate Research Center pathologists provide routine pathology support for Washington National Primate Research Center animals, with ancillary support, expertise, and guidance provided by DCM pathologists and mission-dedicated technicians and laboratories. This integrated comparative pathology unit also provides an excellent training opportunity for students such as those enrolled in the Department of Comparative Medicine post-doctoral training program, which offers training in laboratory animal medicine and comparative pathology. A particularly important function of this comparative pathology unit is support of the Tissue Distribution Program. The TDP provides a wide variety of nonhuman primate tissues to investigative groups within and outside the WaNPRC. This program is an extremely valuable method of conserving the nonhuman primate resource. NHP tissues and biological materials are collected in preparation for RNA/DNA isolation, cell culture, immunohistochemistry/histology, anatomic dissection, and cell sorting. Capabilities of the TDP include, but are not limited to flash frozen preservation, sterile preparation, perfusion, technical surgical dissections, and OCT embedding. In conjunction with the Histology and Imaging core of the University of Washington DCM, research capabilities post-collection include in situ hybridization, confocal and fluorescent microscopy, live cell imaging (DeltaVision), and whole slide scanning with image analysis (Visiopharm, Nikon Elements, and Image Pro). Centralized coordination of nonhuman primate tissue requests with animal availability allows support for a large number of biomedical programs with significantly decreased impact on the animal resource.

Proper citation: WaNPRC Pathology and Tissue Program (RRID:SCR_005589) Copy   

•   Source: SciCrunch Registry

http://mmrrc.ucdavis.edu/

Center that imports, archives, maintains, and distributes mutant mouse alleles as live mice, frozen germplasm, stem cells, and molecular vectors for use in biomedical research. The MMRRC Davis receives transgenics, knockouts, and other kinds of mutant mouse lines at no cost to the donor, and after re-derivation and cryopreservation, distributes breeding stock, germplasm, cells, or tissues of genetically-defined and pathogen-free mice for a small fee to requesting investigators.

Proper citation: University of California at Davis Mutant Mouse Resource and Research Center (RRID:SCR_016448) Copy   

•   Source: SciCrunch Registry

http://www.mmrrc.missouri.edu/

Center that supplies mice and conducts research projects focused on the role of mice as animal models. Some of these projects include refinement of models to ensure study reproducibility, as well as development and improvement of economical methods for cryopreservation of mouse strains.

Proper citation: Mutant Mouse Resource and Research Center - University of Missouri (RRID:SCR_016447) Copy   

•   Source: SciCrunch Registry

http://www.vet.upenn.edu/research/core-resources-facilities/referral-center-for-animal-models

Center that aims to discover, characterize, maintain breeding colonies, and make available dog and cat models with hereditary diseases homologous to those found in human patients that can be used to translate preclinical trials from kennel to clinic. The animal models represent true orthologs of their respective human disease, involving defects in homologous genes resulting in similar molecular, biochemical, pathological, and clinical phenotype as in human patients.

Proper citation: Referral Center for Animal Models of Human Genetic Diseases (RRID:SCR_016453) Copy   

•   Source: SciCrunch Registry

https://www.kbdna.com/

Commercial provider of antibodies, antigens and recombinant proteins from Braintree, Massachusetts . Biotechnology company which provides custom oligonucleotides synthesis service.

Proper citation: kbDNA Inc. (RRID:SCR_016570) Copy   

•   Source: SciCrunch Registry

http://www.mdanderson.org/

The mission of The University of Texas MD Anderson Cancer Center is to eliminate cancer in Texas, the nation, and the world through outstanding programs that integrate patient care, research and prevention, and through education for undergraduate and graduate students, trainees, professionals, employees and the public. VISION: We shall be the premier cancer center in the world, based on the excellence of our people, our research-driven patient care and our science. We are Making Cancer History.

Proper citation: University of Texas MD Anderson Cancer Center (RRID:SCR_004699) Copy   

•   Source: SciCrunch Registry

http://www.loni.usc.edu/

Biomedical technology resource center specializing in novel approaches and tools for neuroimaging. It develops novel strategies to investigate brain structure and function in their full multidimensional complexity. There is a rapidly growing need for brain models comprehensive enough to represent brain structure and function as they change across time in large populations, in different disease states, across imaging modalities, across age and sex, and even across species. International networks of collaborators are provided with a diverse array of tools to create, analyze, visualize, and interact with models of the brain. A major focus of these collaborations is to develop four-dimensional brain models that track and analyze complex patterns of dynamically changing brain structure in development and disease, expanding investigations of brain structure-function relations to four dimensions.

Proper citation: Laboratory of Neuro Imaging (RRID:SCR_001922) Copy   

•   Source: SciCrunch Registry

http://ki.se/ki/jsp/polopoly.jsp?d=29358&a=31598&l=en

THIS RESOURCE IS NO LONGER IN SERVICE, documented August 29, 2016. Project creating a DNA biobank from persons admitted to the neurointensive care unit of the Karolinska University Hospital to study possible genetic influences in traumatic brain injuries (TBI). Serum and cerebrospinal fluid sampled during the subacute phase are also collected. Samples were collected prospectively from clinically well characterized patients to allow for studies of association between candidate genes and clinical outcome parameters or biomarkers for relevant disease processes. The aim is to collect samples from 200-400 individuals. Samples will be collected from TBI patients at up to three different occasions. At first sampling, whole blood, serum and liquor will be collected and at the second and third occasions only serum and liquor.

Proper citation: KI Biobank - TBI (RRID:SCR_005897) Copy   

•   Source: SciCrunch Registry

http://ki.se/en/imm/eims-an-epidemiological-investigation-of-risk-factors-for-multiple-sclerosis

A multi-center population based epidemiological investigation of risk factors for Multiple Sclerosis (MS), where lifestyle- and environmental factors are examined systematically with concurrent genetic information. Newly diagnosed cases of MS in a geographically defined population and randomly chosen controls are identified and asked to answer a questionnaire on lifestyle, previous exposures at work, home and during spare time activities. For both cases and controls blood samples are taken for analysis of putative risk genes since environmental exposures probably contributes to disease only in individuals with certain genotypes. Exposures of interest are different sociodemographic factors, smoking, sunlight exposure, oral contraceptives / hormonal factors, butyrophilin (a milk protein), vaccinations, infections, atopic disease, organic solvents, mineral oils and a number of different psychosocial factors, such as critical lifetime events. Data from more than 1600 cases and 3200 controls are currently collected. (August 2014) The intention is to continue with the data collection over several years in order to analyse how genes and environment interact. The study is a collaboration between different institutions at Karolinska Institutet and neurological centers from 38 different hospitals in Sweden. Sample types * EDTA whole blood * DNA * Plasma * Serum

Proper citation: KI Biobank - EIMS (RRID:SCR_005898) Copy   

•   Source: SciCrunch Registry

http://lasurvey.rand.org/

A dataset of a panel study of a representative sample of all neighborhoods and households in Los Angeles County, with poor neighborhoods and families with children oversampled, for investigating the social and economic determinants of health and race and ethnic disparities. The study follows neighborhoods over time, as well as children and families. Two waves have been conducted to date, in 2000-2001 (L.A.FANS 1) and again beginning in 2006 through early 2009 (L.A. FANS 2). L.A.FANS-2 will significantly enhance the utility of the L.A.FANS data for studies of adult health disparities by: 1) Replicating self-reported health measures from L.A.FANS-1 and collecting new self-reports on treatment, health behaviors, functional limitations, quality and quantity of sleep, anxiety, health status vignettes, and changes in health status since the first interview; 2) Collecting physiological markers of disease and health status, including diabetes, hypertension, obesity, lung function, immune function, and cardiovascular disease; and 3) Expanding the data collected on adults'' work conditions, stressful experiences, and social ties. Wherever possible, L.A.FANS uses well-tested questions or sections from national surveys, such as the Health and Retirement Study (HRS), Panel Study of Income Dynamics (PSID), National Longitudinal Surveys (NLS), and National Health Interview Survey (NHIS), and other urban surveys, such as the Project on Human Development in Chicago Neighborhoods, to facilitate comparisons. Data Availability: Public use data, study design, and questionnaire content from L.A.FANS are available for downloading. Researchers can also apply for a restricted use version of the L.A.FANS-1 data that contain considerable contextual and geographically-referenced information. Application procedures are described at the project Website. L.A.FANS-2 fieldwork was completed at the end of 2008. The PIs anticipate L.A.FANS-2 public use data will be released in summer 2009. * Dates of Study: 2000-2008 * Study Features: Longitudinal, Minority Oversamples, Anthropometric Measures, Biospecimens * Sample Size: ** 2000-1: 2,548 (L.A.FANS 1) ** 2006-8: ~3,600 (L.A.FANS 2) Link: * ICPSR: http://www.icpsr.umich.edu/icpsrweb/ICPSR/studies/00172

Proper citation: Los Angeles Family and Neighborhood Survey (RRID:SCR_008923) Copy   

•   Source: SciCrunch Registry

http://ki.se/en/imm/gems-genes-and-environment-in-multiple-sclerosis

The study subjects invited to participate is chosen from the Swedish national Multiple Sclerosis registry and will number around 10 000 individuals to be included during two to three years. The same number of matched controls will also be included in the study. A pilot study with around 100 participants was performed during 2009, and the large scale study started in November 2009. Multiple sclerosis (MS) is a neurological disease that affects the central nervous system. It affects young people and the debut age is between 20 and 40 years. The disease comes with exacerbations but further on leads to disability. The incidence in Sweden is around 5 per 100 000 per year and the prevalence is 125 per 100 000 inhabitants. In total there are estimated around 13000 cases in Sweden and today 9000 of them are registered in the Swedish National Multiple Sclerosis register. Sample types * EDTA whole blood * DNA * Plasma Number of sample donors: 5592 (June 2010)

Proper citation: KI Biobank - GEMS (RRID:SCR_005893) Copy   

•   Source: SciCrunch Registry

http://www.geisinger.org/research/centers_departments/genomics/mycode/mycode.html

By collecting and analyzing blood samples from Geisinger''s large patient population, MyCode will help unlock the mysteries of some of the most devastating and debilitating diseases. Blood samples are obtained from patients of certain Geisinger specialty clinics to study specific conditions, such as obesity and cardiovascular disease, and also from patients of Geisinger primary care clinics to provide a representative sample of the regional population. More than 60,000 samples from over 23,000 Geisinger patients have been collected so far, and sample collection is ongoing. MyCode researchers use the blood samples to study the genetic causes of diseases and certain disease-related molecular mediators. Knowledge gained from these studies will allow researchers to pursue innovative approaches to disease prevention, diagnosis and treatment. To be of value for Genomic Medicine research, bio-banked samples must be connected to clinical data: MyCode allows genetic and molecular data about the samples to be connected to medical data in a way that protects patient identity. When a patient agrees to participate in MyCode, blood samples for the MyCode Project are collected during blood draws ordered as part of the patient''s routine medical care. After the sample is drawn and labeled, a staff member from the Weis Center for Research transports the blood to the Geisinger Clinic Genomics Core (GCGC) where it is processed for storage. At this stage, all personal identification markers are removed and the samples are assigned a randomly-selected identification number. A secure key is maintained that allows approved researchers to connect the samples to the clinical data for genomic studies in a way that ensures confidentiality of the information. To maintain confidentiality of MyCode data the code linking the research numbers and the electronic health records are kept in a password-protected files accessible only to MyCode team members. Additionally, all results generated from the samples are reported as a group so that individuals are not identified. The samples are stored indefinitely.

Proper citation: Geisinger Biobank (RRID:SCR_005652) Copy   

•   Source: SciCrunch Registry

http://ki.se/ki/jsp/polopoly.jsp?d=29350&a=31591&l=en

THIS RESOURCE IS NO LONGER IN SERVICE, documented August 23, 2016. The aim of the study is to improve the understanding of psychiatric co-morbidity and personality traits as a means to improving prevention and treatment for women with hereditary vulnerability to develop alcohol and / or drug dependence. In depth phenotypic assessment through structured interviews with women with alcohol or drug abuse in order to assess history, psychiatric morbidity and personality traits potentially related to environmental and/or hereditary alcoholism. Association studies of polymorphic markers in candidate genes. Blood samples and interviews performs on 200 women with alcohol dependents to examine mental illness and specific personality characteristics associated to environment and/or hereditary form of alcoholism. Blood samples are also collected from 200 healthy women which functions as controls.

Proper citation: KI Biobank - ALF (RRID:SCR_008880) Copy   

•   Source: SciCrunch Registry

http://ki.se/ki/jsp/polopoly.jsp?d=29350&a=36311&l=en

THIS RESOURCE IS NO LONGER IN SERVICE, documented August 29, 2016. Study to investigate symptoms of Attention Deficit Hyperactivity Disorder (ADHD) according to DSM-IV in adults with special focus on attention deficit. Information is used from the Swedish Twin study of Adults: genes and Environment (STAGE) from the Swedish Twin Registry. ADHD-discordant and concordant samples of pairs of twins for ADHD are selected from STAGE for studies of brain structure and function with Functional Magnetic Resonance Imaging (fMRI).

Proper citation: KI Biobank STAGE-ADHD (RRID:SCR_005921) Copy   

•   Source: SciCrunch Registry

http://www.pathology.med.ohio-state.edu/HTRN/apc/default.asp

THIS RESOURCE IS NO LONGER IN SERVICE, documented August 29, 2016. The Adenoma Polyp Tissue Bank (APTB) receives whole blood from patients enrolled in the Prevention of Sporadic Colorectal Adenomas with Celecoxib clinical trial. We have reached our accrual on blood submissions, so we will no longer be receiving blood specimens The objectives of this trial are as follows: A. To determine the efficacy and safety of celecoxib versus placebo in preventing the occurrence of newly detected colorectal adenomas in subjects at increased risk for colorectal carcinoma. In addition to incidence, other established risk factors will be evaluated for their association with occurrence of new colorectal adenomas, including cancer family history and adenoma size, histopathologic grade, multiplicity and location. Primary assessment of treatment efficacy will be the reduction in the number of subjects with adenomas at colonoscopy after Year 1 and Year 3 of study drug use. Secondary assessments of treatment efficacy will be 1) the number of adenomas 2) the histopathologic grade of adenomas and 3) the size of adenomas, also measured after one year and three years of study drug use. These factors will be incorporated into a risk model for predicting adenoma occurrence and response to celecoxib. B. To determine the efficacy of celecoxib versus placebo in modulating one or more of a panel of biomarkers for colorectal cancer at the cellular and molecular level sampled in a subset of subjects at selective sites at baseline and after Year 1 and Year 3 of study drug use. These biomarkers will include measurements of aberrant crypt foci (ACF), proliferation (index and crypt distribution), apoptosis (index and crypt distribution), COX expression and activity. If modulation of one or more mucosal biomarkers occur, we will explore whether it correlates with the development of incident colorectal neoplasia (adenomas/carcinomas), thereby attempting to validate the surrogacy of that biomarker. C. To develop a specimen bank. Serum and white blood cells are isolated from whole blood and adenoma tissue blocks and slides are banked. Banked specimens will become available for use in correlative science studies at a later point. This project began in 1999 and will be extended through 2006. The lead principal investigator is Monica M. Bertagnolli, MD, Brigham and Women''s Hospital, Boston, MA, and the APTB Director is Scott Jewell, Ph.D., Department of Pathology, The Ohio State University. The APTB is supported by the NIH, NCI Division of Cancer Prevention, in connection with the Strang Cancer Prevention Center, Cornell University, New York., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025.

Proper citation: Adenoma Polyp Tissue Bank (RRID:SCR_005366) Copy   

•   Source: SciCrunch Registry

http://xgc.nci.nih.gov/

NIH initiative to support production of cDNA libraries, clones and 5'/3' sequences and to provide set of full-length (open reading frame) sequences and cDNA clones of expressed genes for Xenopus laevis and Xenopus tropicalis. Clones distribution is outsourced to for profit companies. Project concluded in September 2008. Resources generated by XGC are publicly accessible to biomedical research community. All sequences are deposited into GenBank.Corresponding clones are available through IMAGE clone distribution network. With conclusion of XGC project, GenBank records of XGC sequences will be frozen, without further updates. Since knowledge of what constitutes full-length coding region for some of genes and transcripts for which we have XGC clones will likely change in future, users planning to order XGC clones will need to monitor for these changes. Users can make use of genome browsers and gene-specific databases, such as UCSC Genome browser, NCBI's Map Viewer, and Entrez Gene, to view relevant regions of genome (browsers) or gene-related information (Entrez Gene).

Proper citation: Xenopus Gene Collection (RRID:SCR_007023) Copy   

•   Source: SciCrunch Registry

http://ki.se/ki/jsp/polopoly.jsp?d=29328&a=31530&l=en

THIS RESOURCE IS NO LONGER IN SERVICE, documented August 23, 2016. Longitudinal Assessment of Clinical Course and BIOmarkers in severe Chronic AIRway Disease (BIOAIR) is a study within the European Network For Understanding Mechanisms Of Severe Asthma (ENFUMOSA). BIOAIR study involves studies of severe asthma. The 10% of all asthmatics who have the most difficult disease has a 5-year survival in level with severe cancer diseases, as well as account for half of the costs to society of asthma. Mechanisms for the development of severe asthma, however, is unknown. BIOAIR the project characterizes clinical Phenotype and biomarkers in a study involving 12 centers in nine European countries. In a longitudinal study comparing severe asthmatics with mild asthmatics and patients with COPD (Chronic obstructive pulmonary disease). Clinical data and medicine consumption are collected daily in over a year with the help of modern IT technology. Blood tests, urine samples, upphostningsprover and bronkialbiopsier are collected repeatedly and tested for a wide range of possible pathogenetic factors, including genotype.

Proper citation: BIOAIR - BIOmarkers in severe Chronic AIRway Disease (RRID:SCR_006007) Copy   

•   Source: SciCrunch Registry